Anthracycline-induced cardiomyopathy

Anthracycline cardiomyopathy is less frequently encountered nowadays, due t o the well-recognised dose limitations and cardiac monitoring protocols use d by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for l arge doses to be used for certain individuals. We have demonstrated the ben efit of angiotensin-converting enzyme inhibitor therapy and would consider introducing these compounds at the earliest opportunity. The use of probuco l and vitamins as antioxidants capable of preventing the onset of cardiomyo pathy in humans appears to require further investigation but may significan tly reduce the incidence of this condition in the future.